ホーム › アトピー性皮膚炎（湿疹） › イリノイ州
イリノイ州におけるアトピー性皮膚炎（湿疹）の臨床試験
イリノイ州内の拠点で、アトピー性皮膚炎（湿疹）に関する10件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Sneeze, Wheeze, & Itch Associates, LLC- Site Number : 8400029, Normal
- Rosalind Franklin University of Medicine and Science- Site Number: 8400056, North Chicago
被験者募集中観察研究
12歳以上 · 全性別 · 2026/09/29更新 · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Chicago
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Skokie
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07003425A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Endeavor Health, Skokie
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/08/28更新 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 2, Rolling Meadows
被験者募集中第2相
18歳〜74歳 · 全性別 · 2026/08/12更新 · NCT07037901A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Northwestern University Feinberg School of Medicine /ID# 265117, Chicago
- Sneeze Wheeze & Itch Associates /ID# 267238, Normal
被験者募集中第3相
2歳〜11歳 · 全性別 · 2026/08/06更新 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- DeNova Research /ID# 264513, Chicago
- Northwestern University Feinberg School of Medicine /ID# 264983, Chicago
被験者募集中第3相
18歳〜63歳 · 全性別 · 2026/07/06更新 · NCT06389136Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
- Northwestern University Feinberg School of Medicine: Department of Dermatology, Chicago
被験者募集中第1相
6歳以上 · 全性別 · 2026/07/02更新 · NCT06504160Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
- Lurie Children's Hospital/Northwestern University, Chicago
被験者募集中第4相
6歳〜17歳 · 全性別 · 2026/04/27更新 · NCT05042258Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7058, Chicago
被験者募集中観察研究
12歳以上 · 全性別 · 2026/03/13更新 · NCT06988605ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。